Morning Futures Briefing
with Stephanie Lewicky

Biden's "Buy American" Order; Merck Shuts Down COVID-19 Vaccine Program

U.S. equities are starting the week mixed as traders are preparing for the busiest week of earnings season. This week some of the largest tech companies report (AAPL, FB, MSFT, TSLA), as Nasdaq futures climbed nearly 1% to lead gains overnight adding to last week’s 4% advance. Also, on the top of traders’ minds is President Joe Biden’s “Buy American” order, which takes steps toward strengthening domestic manufacturing and imposing tougher rules on government procurement practices to increase purchases of products made in the U.S. The new policies will include tightening the rules to make it harder for federal agencies to purchase imported products, revising the definition of American-made products, and raising local-content requirements. The executive order also ensures that small and midsize businesses will have better access to information needed to bid for government contracts. A senior Biden administration official said a goal of the Buy American policy is to strengthen the U.S. supply chain after the COVID-19 pandemic revealed weakness in the system for distributing critical medical supplies and safety equipment. “We remain very committed to working with partners and allies to modernize international trade rules to make sure that we can use our taxpayer dollars to stir investments in our own countries and strengthen supply chains,” the official said. Avoiding reliance on other countries that don’t share the same interests is also a goal, the official said.

Merck is dropping out of the COVIDd-19 vaccine race announcing that it will stop developing both formulations of a vaccine it was working on after trial participants failed to generate a strong immune response to either. Early-stage studies of the vaccines indicated they produced inferior immune responses in subjects given the shots compared with people who survived COVID-19 or took authorized COVID-19 vaccines, the company said. The results were “disappointing, and a bit of a surprise,” said Nick Kartsonis, senior vice president of clinical research for infectious diseases and vaccines at Merck Research Laboratories. “We didn’t have what we needed to be able to move forward,” Kartsonis said in an interview Sunday. After evaluating the data, Merck’s senior leadership decided to discontinue the programs and divert resources to the company’s efforts to develop COVID-19 treatments. The shares are lower by 1.0% in the premarket. 

News you can use

Equip yourself with real-time market insights and strategy education—straight from industry pros—with our media affiliate, the TD Ameritrade Network. This programming doesn't just bring you the news, but interprets it to help you think about how you might apply what's going on in the markets to your strategies.

Watch more on TD Ameritrade Network
/6E Overnight Chart
/ES 5 DAY 15 MINUTE CHART. Chart source: The thinkorswim® platform from TD AmeritradeFor illustrative purposes only. Past performance does not guarantee future results.

Global Economic Calendar

*All times are in EST (GMT -5:00)

12:00 AM  - SG CPI

4:00 AM  - DE Ifo Survey

8:30 AM  - US Chicago Fed National Activity Index

10:30 AM  - US Dallas Fed Manufacturing Survey

6:50 PM  - JP BoJ Minutes

1:00 PM US - 2-Yr Note Auction

Knowledge: One of your most valuable assets

Call Us

Content intended for educational/informational purposes only. Not investment advice, or a recommendation of any security, strategy, or account type.

Be sure to understand all risks involved with each strategy, including commission costs, before attempting to place any trade. Clients must consider all relevant risk factors, including their own personal financial situations, before trading.

Futures and futures options trading involves substantial risk, and is not suitable for all investors. Please read the Risk Disclosure for Futures and Options prior to trading futures products. 

Futures accounts are not protected by the Securities Investor Protection Corporation (SIPC).

Futures and futures options trading services provided by TD Ameritrade Futures & Forex LLC. Trading privileges subject to review and approval. Not all clients will qualify.


Market volatility, volume, and system availability may delay account access and trade executions.

Past performance of a security or strategy does not guarantee future results or success.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses. Options trading subject to TD Ameritrade review and approval. Please read Characteristics and Risks of Standardized Options before investing in options.

Supporting documentation for any claims, comparisons, statistics, or other technical data will be supplied upon request.

This is not an offer or solicitation in any jurisdiction where we are not authorized to do business or where such offer or solicitation would be contrary to the local laws and regulations of that jurisdiction, including, but not limited to persons residing in Australia, Canada, Hong Kong, Japan, Saudi Arabia, Singapore, UK, and the countries of the European Union.

TD Ameritrade, Inc., member FINRA/SIPC, a subsidiary of The Charles Schwab Corporation. TD Ameritrade is a trademark jointly owned by TD Ameritrade IP Company, Inc. and The Toronto-Dominion Bank. © 2021 Charles Schwab & Co. Inc. All rights reserved.

Scroll to Top